DNA Sequencing Products & Reviews

The Plasma-SeqSensei™ (PSS) NSCLC RUO (research use only) Kit detects mutations in circulating tumour DNA (ctDNA) from plasma in patients with non-small cell lung cancer.

The Plasma-SeqSensei™ (PSS) Thyroid Cancer RUO (research use only) Kit detects mutations in circulating tumour DNA (ctDNA) from plasma in patients with thyroid cancer.

Maximum purity for optimal safety in preanalytics

LiquidPlex panel is an advanced and user-friendly research assay for targeted next generation sequencing of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly associated with solid tumor type cancers.

FusionPlex Lung v2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 17 genes associated with NSCLC.

FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.

FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.

FusionPlex Pan Solid V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 137 genes associated with various solid tumor malignancies.

VariantPlex Solid Tumor Focus V2 is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 20 genes associated with various solid tumor malignancies.

VariantPlex Core Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 60 genes associated with various solid tumor malignancies.

VariantPlex Expanded Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 76 genes associated with various solid tumor malignancies.

VariantPlex Pan Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 185 genes associated with various solid tumor malignancies.

VariantPlex Complete Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 430 genes associated with various solid tumor malignancies.

Immunoverse is a research assay that characterizes the immune repertoire, including assessment of T- and B-cell clonalities and rare clones, and detection of tumor infiltrating lymphocytes (TIL) and somatic hypermutation with targeted NGS of key T cell receptor and B cell receptor chain RNA relevant for blood cancer and solid tumor research.

VariantPlex Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 75 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).

VariantPlex Core Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 37 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).

FusionPlex Pan Heme is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 199 genes associated with lymphoid and myeloid malignancies.

FusionPlex Heme V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 87 genes associated with lymphoid and myeloid malignancies.

FusionPlex Myeloid is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 84 genes associated with myeloid-origin malignancies.

FusionPlex Lymphoma is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 125 genes associated with lymphomas.

FusionPlex ALL is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 81 genes associated with acute lymphoblastic leukemia (ALL) .

Efficient, and uniform hybridization-based capture for Whole Exome Sequencing Combining more than a decade of probe-design experience with an improved probe-manufacturing process, the new KAPA HyperExome probe pools enable efficient, uniform hybridization-based capture for Whole Exome Sequencing (WES).

Optimized for maximum recovery and sensitive DNA variant detection

KAPA HyperPETE (Primer Extension Target Enrichment) is a novel hybridization capture technology designed to employ primer extension reactions to specifically capture and release target library molecules for sequencing.

KAPA EvoPlus V2 Kits is an enhanced enzymatic DNA library preparation solution that features improved fragmentation performance, insensitivity to inhibitors, increased conversion efficiency & fewer sequencing artifacts.